Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 13Carcinoma, Hepatocellular 6Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Astrocytoma 2Vipoma 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Oropharyngeal Neoplasms 1Oesophagogastric Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1Insulinoma 1Inflammatory Breast Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Vipoma × Bevacizumab × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡